Search Clinical Trials
583,298 trials
ID
Status
Phase
Title
Sponsor
NCT07570992
A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DMNovo Nordisk A/SNot Yet RecruitingPhase 1
NCT07570992Not Yet Recruiting
Phase 1
A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Pa...Novo Nordisk A/S
NCT07569133
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's DiseaseHo-Won LeeEnrolling By InvitationNot Applicable
NCT07569133Enrolling By Invitation
Not Applicable
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressiv...Ho-Won Lee
NCT07569497
Physical Activity Maintenance Intervention for People With StrokeNorthern Ireland Chest Heart and StrokeActive Not RecruitingNot Applicable
NCT07569497Active Not Recruiting
Not Applicable
Physical Activity Maintenance Intervention for People With StrokeNorthern Ireland Chest He...
NCT07571083
Horizontal Plyometric Training and Sprint Mechanics in Early-Adolescent Track-and-Field AthletesFederal University of VicosaCompletedNot Applicable
NCT07571083Completed
Not Applicable
Horizontal Plyometric Training and Sprint Mechanics in Early-Adolescent Track-an...Federal University of Vic...
NCT07570888
This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.Boehringer IngelheimNot Yet RecruitingPhase 4
NCT07570888Not Yet Recruiting
Phase 4
This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycop...Boehringer Ingelheim
NCT07571226
Identification and Molecular Characterisation of Urban-environmental Stress Patterns Affecting Mental IllnessHuashan HospitalNot Yet Recruiting
NCT07571226Not Yet Recruiting
—
Identification and Molecular Characterisation of Urban-environmental Stress Patt...Huashan Hospital
NCT07569341
Validation of the Classification for Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal MetastasesLinkoeping UniversityCompleted
NCT07569341Completed
—
Validation of the Classification for Resectability and Ablatability Criteria for...Linkoeping University
NCT07570862
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisFate TherapeuticsNot Yet RecruitingPhase 2
NCT07570862Not Yet Recruiting
Phase 2
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Neph...Fate Therapeutics
NCT07571161
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseEli Lilly and CompanyNot Yet RecruitingPhase 3
NCT07571161Not Yet Recruiting
Phase 3
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired...Eli Lilly and Company
NCT07570368
Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast CancerUniversitas AirlanggaNot Yet RecruitingNot Applicable
NCT07570368Not Yet Recruiting
Not Applicable
Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to E...Universitas Airlangga
NCT07569458
Online Personalized Psychological Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)Aalborg University HospitalRecruitingNot Applicable
NCT07569458Recruiting
Not Applicable
Online Personalized Psychological Intervention for Patients With Heart Disease a...Aalborg University Hospit...
NCT07570212
Individualized Transcranial Magnetic Stimulation in Parkinsonian DisordersChangping LaboratoryRecruitingNot Applicable
NCT07570212Recruiting
Not Applicable
Individualized Transcranial Magnetic Stimulation in Parkinsonian DisordersChangping Laboratory
NCT07570849
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaShanghai Zhongshan HospitalRecruitingPhase 2
NCT07570849Recruiting
Phase 2
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment f...Shanghai Zhongshan Hospit...
NCT07569328
Low-dose Colchicine for CABG Graft Failure PreventionBeijing Anzhen HospitalNot Yet RecruitingNot Applicable
NCT07569328Not Yet Recruiting
Not Applicable
Low-dose Colchicine for CABG Graft Failure PreventionBeijing Anzhen Hospital
NCT07569224
Testing the Impact of the MOHR Follow-up SupportNational Cancer Institute (NCI)RecruitingNot Applicable
NCT07569224Recruiting
Not Applicable
Testing the Impact of the MOHR Follow-up SupportNational Cancer Institute...
NCT07570784
Stability of Hand Grip Strength Across a Competitive Season in Elite Male and Female Ice Hockey PlayersDalarna County Council, SwedenNot Yet Recruiting
NCT07570784Not Yet Recruiting
—
Stability of Hand Grip Strength Across a Competitive Season in Elite Male and Fe...Dalarna County Council, S...
NCT07570511
Point of Care Testing INR in Antiphospholipid SyndromeCentral Hospital, Nancy, FranceNot Yet RecruitingNot Applicable
NCT07570511Not Yet Recruiting
Not Applicable
Point of Care Testing INR in Antiphospholipid SyndromeCentral Hospital, Nancy,...
NCT07568613
Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate CancerGerman Oncology Center, CyprusRecruitingNot Applicable
NCT07568613Recruiting
Not Applicable
Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Pr...German Oncology Center, C...
NCT07571733
Study on the Efficacy of Spinal Cord Stimulation in Patients With Severe Refractory Primary or Secondary RLSClinica ARS MedicaNot Yet RecruitingNot Applicable
NCT07571733Not Yet Recruiting
Not Applicable
Study on the Efficacy of Spinal Cord Stimulation in Patients With Severe Refract...Clinica ARS Medica
Result Breakdown
Not yet recruiting10 (50%)
Recruiting5 (25%)
Completed2 (10%)
Enrolling by invitation1 (5%)
Active, not recruiting1 (5%)
Unknown1 (5%)
not_applicable11 (55%)
Not Specified4 (20%)
Phase 22 (10%)
Phase 11 (5%)
Phase 41 (5%)
Phase 31 (5%)